Pre-vaccination seroprevalence of 15 human papillomavirus (HPV) types among women in the population-based Slovenian cervical screening program

Highlights • We tested sera from 3259 Slovenian women for 15 HPV type specific antibodies. • Seropositivity for any of 11 hr-HPV and any of 4 lr-HPV types was 59.2% and 33.1%. • Seropositivity for at least one of the HPV types 6, 11, 16, and 18 was 40.8%. • Our estimated HPV16 seroprevalence (25.2%)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2013-10, Vol.31 (43), p.4935-4939
Hauptverfasser:	Učakar, Veronika, Jelen, Mateja M, Faust, Helena, Poljak, Mario, Dillner, Joakim, Klavs, Irena
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Allergy and Immunology Antibodies, Viral - blood Applied microbiology Basic Medicine Biological and medical sciences Cervical cancer Cross-Sectional Studies Cross-sectional study Early Detection of Cancer Female Fundamental and applied biological sciences. Psychology HPV Human papillomavirus Human papillomavirus 16 Humans Immunization Medical and Health Sciences Medical screening Medicin och hälsovetenskap Medicinska och farmaceutiska grundvetenskaper Microbiology Microbiology in the medical area Middle Aged Mikrobiologi inom det medicinska området Miscellaneous Papillomaviridae - classification Papillomaviridae - immunology Papillomavirus Infections - epidemiology Papillomavirus Infections - virology Seroepidemiologic Studies Seroprevalence Slovenia Slovenia - epidemiology Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Virology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • We tested sera from 3259 Slovenian women for 15 HPV type specific antibodies. • Seropositivity for any of 11 hr-HPV and any of 4 lr-HPV types was 59.2% and 33.1%. • Seropositivity for at least one of the HPV types 6, 11, 16, and 18 was 40.8%. • Our estimated HPV16 seroprevalence (25.2%) was higher than in other studies. • We show a substantial lifetime sexual exposure to HPV types included in vaccines.
ISSN:	0264-410X 1873-2518 1873-2518
DOI:	10.1016/j.vaccine.2013.08.038